Prof. Do-Youn Oh discusses the unmet needs for patients with BTCs and what the current treatment algorithm looks like. She also considers possible future treatments that may improve outcomes for these patients.1/3 Next Interview
Prof. Juan Valle discusses the current genetic landscape and actionable signatures of BTC. He also considers how this knowledge is influencing drug development.2/3 Next Interview
Dr Rachna Shroff discusses new and emerging targeted therapies and immunotherapies for the treatment of BTCs. She also considers what are the implications for practice of these new agents.3/3 Take CME Test
Overview & Learning Objectives
In this activity, gastrointestinal oncology experts discuss the current unmet needs in BTC and how the development of new treatments is driven by our understanding of the genetics and tumour microenvironment of BTCs.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity has been designed to meet the educational needs of oncologists, hepatologists and other allied healthcare professionals involved in the management of BTCs.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Do-Youn Oh has no financial interests/relationships or affiliations to disclose in relation to this activity.
Prof. Juan Valle discloses: Consultant/Advisory Boards fees Agios, AstraZeneca, Incyte, Merck, NuCana, QED Therapeutic and Taiho Pharmaceuticals. Speaker’s bureau fees from Incyte and NuCana.
Dr Rachna Shroff discloses: Grants/research support from Exelixis Pharmaceuticals, Halozyme Therapeutics, Merck, Pieris Pharmaceuticals, Rafael Pharmaceuticals and Taiho Pharmaceutical. Consultant/Advisory Boards fees from Agios Pharmaceuticals, AstraZeneca, Clovis Oncology, Debiopharm, Exelixis Pharmaceuticals, Incyte, Merck, QED Therapeutics, Seattle Genetics,
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide contining medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA) European physicians interested in converting AMA PRA Categoty 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 15 September 2020. Date credits expire: 15 September 2021.
After watching this activity, participants should be better able to:
- Describe the unmet therapeutic needs for patients with biliary tract cancer
- Describe the genetic characteristics and tumour microenvironment of biliary tract cancers
- Explain the supporting data for new and emerging treatments for biliary tract cancers